Citations (12)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Rebecca Burne, Sanjeev Balu, Annie Guérin, Rebecca Bungay, Roxana Sin & Mary Lisha Paul. (2021) Comparison of healthcare resource utilization and costs of patients with HR+/HER2- advanced breast cancer treated with ribociclib versus other CDK4/6 inhibitors. Journal of Medical Economics 24:1, pages 806-815.
Read now
Read now
Sun-Kyeong Park, Jae-A Park, So-Young Yang, Ju-Young Shin & Hyein Koh. (2020) The economic impact of disease progression and death in hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer patients: using Korean nationwide health insurance claims data. Current Medical Research and Opinion 36:11, pages 1825-1833.
Read now
Read now
Vibeke Strand, Ruchitbhai Shah, Chris Atzinger, Jifang Zhou, Jerry Clewell, Arijit Ganguli & Namita Tundia. (2020) Economic burden of fatigue or morning stiffness among patients with rheumatoid arthritis: a retrospective analysis from real-world data. Current Medical Research and Opinion 36:1, pages 161-168.
Read now
Read now
Articles from other publishers (9)
Gustavo Werutsky, Tomás Reinert, Mahira Lopes Rosa & Carlos Henrique Barrios. (2021) Real-world Data on First-line Systemic Therapy for Hormone Receptor-positive HER2-negative Metastatic Breast Cancer: A Trend Shift in the Era of CDK 4/6 Inhibitors. Clinical Breast Cancer 21:6, pages e688-e692.
Crossref
Crossref
Michelino De Laurentiis, Simona Borstnar, Mario Campone, Ellen Warner, Javier Salvador Bofill, William Jacot, Susan Dent, Miguel Martin, Alistair Ring, Paul Cottu, Janice Lu, Eva Ciruelos, Hamdy A. Azim, Sanjoy Chatterjee, Katie Zhou, Jiwen Wu, Lakshmi Menon-Singh & Claudio Zamagni. (2021) Full population results from the core phase of CompLEEment-1, a phase 3b study of ribociclib plus letrozole as first-line therapy for advanced breast cancer in an expanded population. Breast Cancer Research and Treatment 189:3, pages 689-699.
Crossref
Crossref
Lisa M Hess, Xiaohong Li, Yixun Wu, Robert J Goodloe & Zhanglin Lin Cui. (2021) Defining treatment regimens and lines of therapy using real-world data in oncology. Future Oncology 17:15, pages 1865-1877.
Crossref
Crossref
Karen E Skinner, Amin Haiderali, Min Huang & Lee S Schwartzberg. (2021) Assessing direct costs of treating metastatic triple-negative breast cancer in the USA. Journal of Comparative Effectiveness Research 10:2, pages 109-118.
Crossref
Crossref
Hsuan-Ming Chen, Jin-Hua Chen, Shao-Chin Chiang, Yi-Chun Lin & Yu Ko. (2021) An evaluation of the healthcare costs of metastatic breast cancer. Medicine 100:43, pages e27567.
Crossref
Crossref
Stacey A. Dacosta Byfield, Oluwakayode Adejoro, Ronda Copher, Debanjana Chatterjee, Prashant R. Joshi & Francis P. Worden. (2019) Real-World Treatment Patterns Among Patients Initiating Small Molecule Kinase Inhibitor Therapies for Thyroid Cancer in the United States. Advances in Therapy 36:4, pages 896-915.
Crossref
Crossref
Anand A. Dalal, Geneviève Gauthier, Patrick Gagnon-Sanschagrin, Rebecca Burne, Annie Guérin, Polly Niravath & Tania Small. (2018) Treatment and Monitoring Patterns Among Premenopausal Women with HR+/HER2− Advanced Breast Cancer. Advances in Therapy 35:9, pages 1356-1367.
Crossref
Crossref
Geneviève Gauthier, Patrick Gagnon-Sanschagrin, Annie Guérin, Rebecca Burne, Tania Small, Polly Niravath & Anand A. Dalal. (2018) Economic Burden of HR+/HER2- Metastatic Breast Cancer Among Adult Premenopausal Women. Advances in Therapy 35:4, pages 503-514.
Crossref
Crossref
Deborah Goldschmidt, Anand A. Dalal, Hela Romdhani, Sneha Kelkar, Annie Guerin, Genevieve Gauthier, Eric Q. Wu, Polly Niravath & Tania Small. (2018) Current Treatment Patterns Among Postmenopausal Women with HR+/HER2− Metastatic Breast Cancer in US Community Oncology Practices: An Observational Study. Advances in Therapy 35:4, pages 482-493.
Crossref
Crossref